| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Defects, Congenital | 45 | 2023 | 1781 | 3.320 |
Why?
|
| Pulmonary Circulation | 18 | 2019 | 132 | 2.800 |
Why?
|
| Pulmonary Artery | 22 | 2020 | 521 | 2.480 |
Why?
|
| Cardiology | 6 | 2024 | 552 | 1.680 |
Why?
|
| Blood Pressure | 24 | 2018 | 1598 | 1.540 |
Why?
|
| Models, Cardiovascular | 13 | 2018 | 189 | 1.540 |
Why?
|
| Fontan Procedure | 11 | 2023 | 178 | 1.490 |
Why?
|
| Rheumatic Heart Disease | 5 | 2019 | 46 | 1.440 |
Why?
|
| Hypertension, Pulmonary | 16 | 2023 | 470 | 1.380 |
Why?
|
| Heart Ventricles | 12 | 2017 | 846 | 1.340 |
Why?
|
| Oxygen Consumption | 12 | 2023 | 420 | 1.210 |
Why?
|
| Hypoplastic Left Heart Syndrome | 9 | 2017 | 253 | 1.200 |
Why?
|
| Intensive Care Units, Pediatric | 10 | 2024 | 478 | 1.180 |
Why?
|
| Fetus | 7 | 2012 | 675 | 1.150 |
Why?
|
| Dobutamine | 7 | 2011 | 59 | 1.120 |
Why?
|
| Cardiopulmonary Bypass | 11 | 2014 | 393 | 1.090 |
Why?
|
| Monitoring, Physiologic | 5 | 2021 | 538 | 1.090 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2016 | 122 | 1.060 |
Why?
|
| Sheep | 22 | 2018 | 273 | 1.050 |
Why?
|
| Ventricular Function | 5 | 2018 | 100 | 1.030 |
Why?
|
| Blood Flow Velocity | 16 | 2019 | 542 | 0.960 |
Why?
|
| Aorta | 9 | 2020 | 682 | 0.950 |
Why?
|
| Ductus Arteriosus | 4 | 2019 | 65 | 0.930 |
Why?
|
| Heart Atria | 5 | 2013 | 356 | 0.910 |
Why?
|
| Transposition of Great Vessels | 7 | 2020 | 131 | 0.900 |
Why?
|
| Hemodynamics | 18 | 2023 | 966 | 0.900 |
Why?
|
| Mass Screening | 6 | 2016 | 1547 | 0.850 |
Why?
|
| Coronary Circulation | 6 | 2018 | 256 | 0.790 |
Why?
|
| Aortic Coarctation | 2 | 2016 | 105 | 0.720 |
Why?
|
| Ventricular Function, Right | 5 | 2012 | 113 | 0.710 |
Why?
|
| Antihypertensive Agents | 5 | 2016 | 441 | 0.710 |
Why?
|
| Meconium Aspiration Syndrome | 4 | 2010 | 16 | 0.700 |
Why?
|
| Leadership | 2 | 2022 | 263 | 0.670 |
Why?
|
| Vascular Resistance | 9 | 2015 | 215 | 0.650 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2014 | 140 | 0.650 |
Why?
|
| Regional Blood Flow | 9 | 2017 | 284 | 0.650 |
Why?
|
| Ventricular Dysfunction, Right | 4 | 2004 | 83 | 0.650 |
Why?
|
| Heart Arrest | 2 | 2021 | 381 | 0.650 |
Why?
|
| Vasoconstriction | 3 | 2010 | 120 | 0.640 |
Why?
|
| Critical Care | 5 | 2024 | 811 | 0.630 |
Why?
|
| Endothelin-1 | 3 | 2014 | 62 | 0.620 |
Why?
|
| Patient Care Team | 3 | 2022 | 828 | 0.620 |
Why?
|
| Child | 54 | 2024 | 30576 | 0.610 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 2 | 2014 | 20 | 0.600 |
Why?
|
| Heart Septal Defects, Ventricular | 4 | 2011 | 137 | 0.600 |
Why?
|
| Ventricular Function, Left | 8 | 2014 | 570 | 0.590 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 21 | 0.590 |
Why?
|
| Cardiovascular Diseases | 5 | 2016 | 2286 | 0.580 |
Why?
|
| Pediatrics | 5 | 2024 | 1187 | 0.580 |
Why?
|
| Cerebral Arteries | 1 | 2017 | 100 | 0.560 |
Why?
|
| Arterial Pressure | 1 | 2017 | 106 | 0.560 |
Why?
|
| Child, Preschool | 37 | 2023 | 17070 | 0.550 |
Why?
|
| Cardiologists | 1 | 2016 | 32 | 0.550 |
Why?
|
| Comprehension | 1 | 2017 | 104 | 0.550 |
Why?
|
| Nitric Oxide | 9 | 2014 | 666 | 0.540 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2013 | 225 | 0.540 |
Why?
|
| Humans | 141 | 2024 | 271967 | 0.530 |
Why?
|
| Heart Rate | 9 | 2019 | 756 | 0.530 |
Why?
|
| Ambulatory Care | 2 | 2017 | 599 | 0.530 |
Why?
|
| Health Literacy | 1 | 2017 | 116 | 0.520 |
Why?
|
| School Health Services | 1 | 2016 | 112 | 0.510 |
Why?
|
| Ductus Arteriosus, Patent | 3 | 2023 | 144 | 0.510 |
Why?
|
| Bile Acids and Salts | 2 | 2016 | 261 | 0.500 |
Why?
|
| Exercise Tolerance | 4 | 2023 | 109 | 0.500 |
Why?
|
| Infant, Newborn | 32 | 2021 | 8631 | 0.500 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2006 | 72 | 0.490 |
Why?
|
| Community Health Services | 1 | 2016 | 129 | 0.480 |
Why?
|
| Global Health | 2 | 2017 | 691 | 0.480 |
Why?
|
| Postoperative Complications | 10 | 2017 | 5695 | 0.470 |
Why?
|
| Cerebrovascular Circulation | 2 | 2017 | 512 | 0.470 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2009 | 505 | 0.460 |
Why?
|
| Cardiac Catheterization | 7 | 2023 | 692 | 0.460 |
Why?
|
| Cardiovascular System | 3 | 2023 | 147 | 0.450 |
Why?
|
| Echocardiography | 13 | 2020 | 1238 | 0.450 |
Why?
|
| Infant | 39 | 2023 | 13995 | 0.440 |
Why?
|
| Diastole | 8 | 2018 | 188 | 0.430 |
Why?
|
| Family | 1 | 2017 | 778 | 0.420 |
Why?
|
| Urotensins | 2 | 2010 | 4 | 0.420 |
Why?
|
| Vasodilator Agents | 7 | 2016 | 234 | 0.410 |
Why?
|
| Oxygen | 9 | 2023 | 795 | 0.410 |
Why?
|
| Myocardium | 4 | 2018 | 1244 | 0.400 |
Why?
|
| Communication | 2 | 2020 | 855 | 0.400 |
Why?
|
| Cardiac Output | 10 | 2017 | 196 | 0.400 |
Why?
|
| Disease Management | 1 | 2017 | 1109 | 0.390 |
Why?
|
| Tetralogy of Fallot | 6 | 2017 | 158 | 0.390 |
Why?
|
| Victoria | 6 | 2013 | 18 | 0.380 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 239 | 0.380 |
Why?
|
| Female | 79 | 2024 | 149251 | 0.370 |
Why?
|
| Kingella kingae | 1 | 2010 | 2 | 0.370 |
Why?
|
| Cardiomyopathies | 4 | 2019 | 556 | 0.360 |
Why?
|
| Neisseriaceae Infections | 1 | 2010 | 4 | 0.360 |
Why?
|
| Cardiovascular Surgical Procedures | 3 | 2011 | 47 | 0.360 |
Why?
|
| Male | 71 | 2024 | 129048 | 0.360 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2012 | 172 | 0.360 |
Why?
|
| Vascular Surgical Procedures | 1 | 2016 | 617 | 0.360 |
Why?
|
| Endocarditis, Bacterial | 2 | 2010 | 152 | 0.350 |
Why?
|
| Vascular Fistula | 1 | 2010 | 34 | 0.350 |
Why?
|
| Hypertension | 2 | 2018 | 1619 | 0.350 |
Why?
|
| Cardiac Surgical Procedures | 8 | 2019 | 1164 | 0.350 |
Why?
|
| Parents | 1 | 2017 | 1077 | 0.340 |
Why?
|
| Heart Failure | 5 | 2018 | 2380 | 0.340 |
Why?
|
| Cardiac Complexes, Premature | 1 | 2009 | 7 | 0.340 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2005 | 407 | 0.340 |
Why?
|
| Cardiotonic Agents | 5 | 2018 | 160 | 0.340 |
Why?
|
| Myocardial Contraction | 5 | 2018 | 301 | 0.340 |
Why?
|
| Piperazines | 5 | 2006 | 2147 | 0.330 |
Why?
|
| Sulfonamides | 5 | 2023 | 1929 | 0.330 |
Why?
|
| Nitric Oxide Synthase | 2 | 2001 | 329 | 0.330 |
Why?
|
| Lung | 7 | 2015 | 3298 | 0.330 |
Why?
|
| Respiration, Artificial | 8 | 2006 | 583 | 0.330 |
Why?
|
| Abscess | 1 | 2010 | 192 | 0.320 |
Why?
|
| Endothelial Cells | 1 | 2014 | 1038 | 0.310 |
Why?
|
| Heart Septal Defects, Atrial | 4 | 2003 | 129 | 0.310 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 707 | 0.300 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2007 | 209 | 0.300 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2012 | 434 | 0.300 |
Why?
|
| Cardiology Service, Hospital | 2 | 2006 | 16 | 0.290 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2007 | 920 | 0.290 |
Why?
|
| Adolescent | 32 | 2021 | 32743 | 0.290 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2016 | 339 | 0.290 |
Why?
|
| Sepsis | 2 | 2023 | 689 | 0.290 |
Why?
|
| Malawi | 3 | 2019 | 388 | 0.290 |
Why?
|
| Computer Simulation | 6 | 2023 | 1572 | 0.290 |
Why?
|
| Blood Gas Analysis | 6 | 2014 | 106 | 0.280 |
Why?
|
| Cardiac Care Facilities | 1 | 2006 | 8 | 0.280 |
Why?
|
| Systole | 6 | 2017 | 221 | 0.280 |
Why?
|
| Time Factors | 13 | 2019 | 13129 | 0.280 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2005 | 639 | 0.280 |
Why?
|
| Postoperative Period | 10 | 2020 | 671 | 0.280 |
Why?
|
| Infusions, Intravenous | 9 | 2007 | 1438 | 0.270 |
Why?
|
| Hydrazones | 3 | 2014 | 43 | 0.270 |
Why?
|
| Animals | 35 | 2019 | 62782 | 0.270 |
Why?
|
| Animals, Newborn | 5 | 2013 | 1394 | 0.270 |
Why?
|
| Length of Stay | 3 | 2016 | 2013 | 0.270 |
Why?
|
| Pulmonary Valve Stenosis | 2 | 2003 | 43 | 0.270 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 747 | 0.260 |
Why?
|
| Aorta, Thoracic | 1 | 2010 | 532 | 0.260 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2006 | 131 | 0.250 |
Why?
|
| Pulmonary Valve | 3 | 2020 | 99 | 0.250 |
Why?
|
| Peptides, Cyclic | 2 | 2004 | 139 | 0.250 |
Why?
|
| ROC Curve | 3 | 2021 | 1247 | 0.250 |
Why?
|
| Alaska Natives | 1 | 2024 | 4 | 0.250 |
Why?
|
| Textbooks as Topic | 1 | 2024 | 9 | 0.240 |
Why?
|
| Vena Cava, Superior | 3 | 1997 | 78 | 0.240 |
Why?
|
| Antiviral Agents | 1 | 2012 | 1255 | 0.240 |
Why?
|
| Body Temperature | 3 | 2004 | 164 | 0.240 |
Why?
|
| Cardiac Output, Low | 2 | 2007 | 77 | 0.240 |
Why?
|
| Algorithms | 6 | 2021 | 3926 | 0.240 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 4989 | 0.240 |
Why?
|
| Indians, North American | 1 | 2024 | 91 | 0.230 |
Why?
|
| Retrospective Studies | 23 | 2023 | 39817 | 0.230 |
Why?
|
| Pulsatile Flow | 4 | 2012 | 143 | 0.220 |
Why?
|
| Infant, Very Low Birth Weight | 3 | 2021 | 170 | 0.220 |
Why?
|
| Pyridazines | 3 | 2014 | 319 | 0.220 |
Why?
|
| Critical Illness | 4 | 2023 | 744 | 0.220 |
Why?
|
| Electrocardiography | 6 | 2017 | 1192 | 0.220 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2003 | 41 | 0.220 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2019 | 22 | 0.210 |
Why?
|
| Receptors, Endothelin | 1 | 2002 | 25 | 0.210 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2002 | 26 | 0.210 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2004 | 194 | 0.210 |
Why?
|
| Pregnancy | 9 | 2013 | 8110 | 0.210 |
Why?
|
| Mutation | 6 | 2019 | 15952 | 0.210 |
Why?
|
| Heart Conduction System | 1 | 2003 | 161 | 0.200 |
Why?
|
| Blood Pressure Determination | 2 | 2021 | 115 | 0.200 |
Why?
|
| Models, Animal | 3 | 2012 | 673 | 0.200 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2005 | 271 | 0.200 |
Why?
|
| Organizational Culture | 1 | 2022 | 120 | 0.200 |
Why?
|
| Prevalence | 6 | 2019 | 3417 | 0.200 |
Why?
|
| Prospective Studies | 16 | 2024 | 13398 | 0.200 |
Why?
|
| Software Validation | 1 | 2021 | 34 | 0.190 |
Why?
|
| Hypovolemia | 1 | 2021 | 12 | 0.190 |
Why?
|
| Echocardiography, Doppler | 5 | 2009 | 186 | 0.190 |
Why?
|
| Disease Models, Animal | 6 | 2018 | 7474 | 0.190 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 15264 | 0.190 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2018 | 490 | 0.190 |
Why?
|
| Sildenafil Citrate | 6 | 2016 | 53 | 0.190 |
Why?
|
| Coronary Vessels | 2 | 2018 | 639 | 0.190 |
Why?
|
| Postoperative Care | 4 | 2018 | 730 | 0.190 |
Why?
|
| Airway Obstruction | 2 | 2002 | 272 | 0.190 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2002 | 89 | 0.190 |
Why?
|
| Coronary Angiography | 2 | 2016 | 567 | 0.190 |
Why?
|
| Blood Vessels | 2 | 2011 | 235 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3395 | 0.180 |
Why?
|
| Pulmonary Atresia | 1 | 2000 | 47 | 0.180 |
Why?
|
| Exercise Test | 3 | 2023 | 313 | 0.180 |
Why?
|
| Prenatal Diagnosis | 3 | 2013 | 609 | 0.180 |
Why?
|
| Ventilators, Negative-Pressure | 1 | 2000 | 5 | 0.180 |
Why?
|
| Adrenergic Antagonists | 1 | 2000 | 19 | 0.180 |
Why?
|
| Treatment Outcome | 20 | 2021 | 33911 | 0.170 |
Why?
|
| Swine | 7 | 2008 | 1609 | 0.170 |
Why?
|
| Asymptomatic Diseases | 2 | 2019 | 104 | 0.170 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2019 | 17 | 0.170 |
Why?
|
| Erythrocyte Transfusion | 1 | 2021 | 211 | 0.170 |
Why?
|
| Aortic Valve | 3 | 2020 | 486 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 4391 | 0.160 |
Why?
|
| Bioprosthesis | 1 | 2020 | 131 | 0.160 |
Why?
|
| Milrinone | 2 | 2011 | 31 | 0.160 |
Why?
|
| Administration, Inhalation | 7 | 2006 | 299 | 0.160 |
Why?
|
| Adaptation, Physiological | 2 | 2018 | 349 | 0.160 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 6203 | 0.160 |
Why?
|
| Arteries | 2 | 2012 | 293 | 0.160 |
Why?
|
| Infant, Premature, Diseases | 1 | 2021 | 251 | 0.160 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2020 | 229 | 0.160 |
Why?
|
| Cholic Acids | 1 | 2018 | 32 | 0.160 |
Why?
|
| Heart | 5 | 2023 | 1201 | 0.160 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 86 | 0.160 |
Why?
|
| Crowdsourcing | 1 | 2018 | 19 | 0.160 |
Why?
|
| Lead | 1 | 2018 | 44 | 0.160 |
Why?
|
| Heart-Assist Devices | 2 | 2022 | 1050 | 0.160 |
Why?
|
| Pyrimidines | 3 | 2023 | 3663 | 0.160 |
Why?
|
| Heterotaxy Syndrome | 1 | 2019 | 63 | 0.150 |
Why?
|
| Pulse Wave Analysis | 1 | 2018 | 49 | 0.150 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 244 | 0.150 |
Why?
|
| Exome | 3 | 2019 | 1252 | 0.150 |
Why?
|
| Machine Learning | 1 | 2021 | 362 | 0.150 |
Why?
|
| Zebrafish Proteins | 1 | 2019 | 157 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 5774 | 0.150 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2011 | 147 | 0.150 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2017 | 46 | 0.150 |
Why?
|
| Sulfones | 5 | 2006 | 146 | 0.150 |
Why?
|
| Hypotension | 2 | 2015 | 237 | 0.150 |
Why?
|
| Models, Organizational | 1 | 2017 | 75 | 0.140 |
Why?
|
| Hepatic Veins | 1 | 2017 | 59 | 0.140 |
Why?
|
| Exercise | 3 | 2023 | 1213 | 0.140 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 4503 | 0.140 |
Why?
|
| Nonlinear Dynamics | 3 | 2015 | 78 | 0.140 |
Why?
|
| Long QT Syndrome | 1 | 2018 | 111 | 0.140 |
Why?
|
| History, 20th Century | 2 | 2024 | 550 | 0.140 |
Why?
|
| Everolimus | 1 | 2019 | 438 | 0.140 |
Why?
|
| Vasodilation | 3 | 2010 | 217 | 0.140 |
Why?
|
| Purines | 5 | 2006 | 271 | 0.140 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 319 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 1 | 2019 | 341 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 158 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2020 | 326 | 0.140 |
Why?
|
| Intubation, Intratracheal | 1 | 2021 | 460 | 0.140 |
Why?
|
| Embolization, Therapeutic | 1 | 2002 | 606 | 0.140 |
Why?
|
| Growth Differentiation Factors | 1 | 2016 | 12 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 404 | 0.130 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2023 | 158 | 0.130 |
Why?
|
| Preoperative Care | 4 | 2023 | 1553 | 0.130 |
Why?
|
| Biliary Atresia | 1 | 2019 | 201 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 64 | 0.130 |
Why?
|
| Transition to Adult Care | 1 | 2018 | 113 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 210 | 0.130 |
Why?
|
| Observer Variation | 2 | 2016 | 720 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2016 | 111 | 0.130 |
Why?
|
| Hospitals, Pediatric | 2 | 2018 | 795 | 0.130 |
Why?
|
| Incidence | 3 | 2019 | 5858 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2017 | 296 | 0.130 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2010 | 291 | 0.130 |
Why?
|
| Respiratory System | 1 | 2016 | 130 | 0.130 |
Why?
|
| Genome-Wide Association Study | 2 | 2016 | 2348 | 0.130 |
Why?
|
| Quality of Life | 1 | 2009 | 4753 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2018 | 293 | 0.120 |
Why?
|
| Genetic Variation | 3 | 2019 | 2160 | 0.120 |
Why?
|
| Capillaries | 1 | 2015 | 104 | 0.120 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 485 | 0.120 |
Why?
|
| Kv1.5 Potassium Channel | 1 | 2014 | 8 | 0.120 |
Why?
|
| Fetal Heart | 1 | 1995 | 113 | 0.120 |
Why?
|
| Genetic Testing | 3 | 2019 | 1699 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2016 | 499 | 0.120 |
Why?
|
| Hospitalization | 2 | 2016 | 2187 | 0.120 |
Why?
|
| Tachycardia, Ventricular | 1 | 2017 | 206 | 0.120 |
Why?
|
| Amino Acids | 1 | 2018 | 788 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2010 | 4897 | 0.120 |
Why?
|
| Microcirculation | 1 | 2015 | 195 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2010 | 2330 | 0.120 |
Why?
|
| Health Surveys | 1 | 2016 | 403 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 324 | 0.120 |
Why?
|
| Age Distribution | 1 | 2016 | 730 | 0.120 |
Why?
|
| Cholic Acid | 1 | 2014 | 18 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2016 | 250 | 0.120 |
Why?
|
| Learning | 1 | 2017 | 433 | 0.110 |
Why?
|
| Gonadal Dysgenesis | 1 | 2013 | 4 | 0.110 |
Why?
|
| Weill-Marchesani Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 449 | 0.110 |
Why?
|
| Norwood Procedures | 2 | 2013 | 101 | 0.110 |
Why?
|
| Receptor, Endothelin A | 2 | 2004 | 18 | 0.110 |
Why?
|
| Consensus | 1 | 2018 | 1113 | 0.110 |
Why?
|
| Mexican Americans | 1 | 2016 | 334 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2019 | 735 | 0.110 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 87 | 0.110 |
Why?
|
| Anxiety | 1 | 2021 | 1230 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4346 | 0.110 |
Why?
|
| Ischemic Preconditioning | 1 | 2013 | 21 | 0.110 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2013 | 65 | 0.110 |
Why?
|
| Cyanosis | 1 | 2013 | 43 | 0.110 |
Why?
|
| Coronary Care Units | 1 | 2012 | 51 | 0.110 |
Why?
|
| Infant Mortality | 1 | 2013 | 178 | 0.100 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2002 | 64 | 0.100 |
Why?
|
| Psychometrics | 1 | 2017 | 962 | 0.100 |
Why?
|
| Plasmids | 1 | 2014 | 953 | 0.100 |
Why?
|
| Homeostasis | 1 | 2017 | 959 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 431 | 0.100 |
Why?
|
| Palivizumab | 1 | 2012 | 61 | 0.100 |
Why?
|
| Patient Admission | 1 | 2013 | 235 | 0.100 |
Why?
|
| Ventilator Weaning | 3 | 2002 | 33 | 0.100 |
Why?
|
| Hypoxia, Brain | 1 | 2011 | 36 | 0.100 |
Why?
|
| Biomarkers | 6 | 2018 | 5098 | 0.100 |
Why?
|
| Certification | 1 | 2012 | 109 | 0.100 |
Why?
|
| United States | 4 | 2024 | 16018 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2012 | 208 | 0.100 |
Why?
|
| Cholestasis | 1 | 2014 | 206 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 603 | 0.100 |
Why?
|
| Marfan Syndrome | 1 | 2013 | 146 | 0.100 |
Why?
|
| Anastomosis, Surgical | 4 | 2007 | 371 | 0.100 |
Why?
|
| Thoracic Surgery | 2 | 2013 | 280 | 0.100 |
Why?
|
| Airway Extubation | 1 | 2012 | 74 | 0.100 |
Why?
|
| Eisenmenger Complex | 1 | 2011 | 7 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 1032 | 0.100 |
Why?
|
| Cardiac Volume | 1 | 2011 | 19 | 0.100 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2011 | 14 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2016 | 2288 | 0.100 |
Why?
|
| Oral Hygiene | 1 | 2011 | 22 | 0.090 |
Why?
|
| Action Potentials | 3 | 2004 | 597 | 0.090 |
Why?
|
| Aptamers, Peptide | 1 | 2010 | 3 | 0.090 |
Why?
|
| Enkephalin, Methionine | 1 | 2010 | 12 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2016 | 706 | 0.090 |
Why?
|
| Heart Function Tests | 2 | 2008 | 75 | 0.090 |
Why?
|
| Depression | 1 | 2021 | 1729 | 0.090 |
Why?
|
| Nitroarginine | 2 | 2001 | 12 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 5103 | 0.090 |
Why?
|
| Benchmarking | 1 | 2012 | 285 | 0.090 |
Why?
|
| Mitral Valve | 1 | 1992 | 285 | 0.090 |
Why?
|
| American Heart Association | 1 | 2012 | 329 | 0.090 |
Why?
|
| Heart Bypass, Right | 1 | 2010 | 18 | 0.090 |
Why?
|
| Rupture, Spontaneous | 1 | 2010 | 69 | 0.090 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2010 | 30 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2011 | 115 | 0.090 |
Why?
|
| Carbon Dioxide | 2 | 2009 | 331 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 498 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2010 | 58 | 0.090 |
Why?
|
| Lower Extremity | 1 | 2013 | 284 | 0.090 |
Why?
|
| Texas | 3 | 2016 | 6435 | 0.090 |
Why?
|
| Ventricular Pressure | 2 | 2001 | 44 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2007 | 1941 | 0.090 |
Why?
|
| Sinus of Valsalva | 1 | 2010 | 36 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2018 | 5783 | 0.090 |
Why?
|
| Survival Rate | 6 | 2017 | 12545 | 0.090 |
Why?
|
| Adenosine | 1 | 2012 | 300 | 0.090 |
Why?
|
| Chromosome Disorders | 1 | 2012 | 426 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2019 | 1186 | 0.090 |
Why?
|
| Debridement | 1 | 2010 | 119 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2674 | 0.080 |
Why?
|
| Fatal Outcome | 3 | 2013 | 835 | 0.080 |
Why?
|
| Hypogonadism | 1 | 2013 | 309 | 0.080 |
Why?
|
| Endocarditis | 1 | 2011 | 128 | 0.080 |
Why?
|
| Exons | 1 | 2013 | 1389 | 0.080 |
Why?
|
| Catheterization | 2 | 2003 | 425 | 0.080 |
Why?
|
| DNA | 1 | 2018 | 3090 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2011 | 214 | 0.080 |
Why?
|
| Oscillometry | 1 | 2008 | 23 | 0.080 |
Why?
|
| Transfection | 1 | 2014 | 3167 | 0.080 |
Why?
|
| Respiration | 1 | 1991 | 465 | 0.080 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 219 | 0.080 |
Why?
|
| Biological Clocks | 1 | 2008 | 39 | 0.080 |
Why?
|
| Respiratory Mechanics | 2 | 2000 | 174 | 0.080 |
Why?
|
| Angiography | 2 | 2019 | 353 | 0.080 |
Why?
|
| Heart Auscultation | 1 | 2008 | 8 | 0.080 |
Why?
|
| Heart Murmurs | 1 | 2008 | 15 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2013 | 745 | 0.080 |
Why?
|
| Urea | 1 | 2010 | 304 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 321 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 622 | 0.080 |
Why?
|
| Drug Design | 1 | 2010 | 378 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1085 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2014 | 774 | 0.070 |
Why?
|
| Infant, Premature | 2 | 2021 | 830 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2010 | 331 | 0.070 |
Why?
|
| Manometry | 1 | 2007 | 72 | 0.070 |
Why?
|
| Terminal Care | 1 | 2012 | 465 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2013 | 1198 | 0.070 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2007 | 66 | 0.070 |
Why?
|
| Body Size | 1 | 2007 | 69 | 0.070 |
Why?
|
| Heart Block | 1 | 2007 | 46 | 0.070 |
Why?
|
| Growth | 1 | 2007 | 125 | 0.070 |
Why?
|
| Hypoxia | 1 | 2010 | 476 | 0.070 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2013 | 523 | 0.070 |
Why?
|
| Age Factors | 5 | 2007 | 5516 | 0.070 |
Why?
|
| Rhamnose | 1 | 1986 | 6 | 0.070 |
Why?
|
| Balloon Occlusion | 1 | 2007 | 61 | 0.070 |
Why?
|
| Adult | 15 | 2020 | 81964 | 0.070 |
Why?
|
| Disaccharides | 1 | 1986 | 30 | 0.070 |
Why?
|
| Abnormalities, Multiple | 2 | 2005 | 1016 | 0.070 |
Why?
|
| Lactulose | 1 | 1986 | 40 | 0.070 |
Why?
|
| Electroencephalography | 1 | 2011 | 995 | 0.070 |
Why?
|
| Pyridines | 1 | 2014 | 1311 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2157 | 0.070 |
Why?
|
| Quinolines | 1 | 2010 | 401 | 0.070 |
Why?
|
| Gases | 1 | 2006 | 39 | 0.070 |
Why?
|
| Fetal Diseases | 3 | 2001 | 449 | 0.070 |
Why?
|
| Fetal Blood | 1 | 2009 | 502 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 125 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2019 | 9476 | 0.070 |
Why?
|
| RNA Interference | 1 | 2010 | 1397 | 0.070 |
Why?
|
| Infant Welfare | 2 | 2002 | 28 | 0.070 |
Why?
|
| Intestinal Absorption | 1 | 1986 | 223 | 0.070 |
Why?
|
| Telemedicine | 1 | 2012 | 547 | 0.070 |
Why?
|
| Obesity | 1 | 2018 | 2944 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 559 | 0.070 |
Why?
|
| Incontinentia Pigmenti | 1 | 2005 | 15 | 0.060 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2005 | 10 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1556 | 0.060 |
Why?
|
| Gestational Age | 1 | 2009 | 1162 | 0.060 |
Why?
|
| Equipment Safety | 1 | 2005 | 66 | 0.060 |
Why?
|
| Nitrous Oxide | 1 | 2005 | 18 | 0.060 |
Why?
|
| Replantation | 1 | 2005 | 58 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2012 | 920 | 0.060 |
Why?
|
| Reoperation | 3 | 2005 | 1392 | 0.060 |
Why?
|
| Dopamine | 2 | 2014 | 340 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2019 | 1243 | 0.060 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2004 | 10 | 0.060 |
Why?
|
| Feedback, Physiological | 2 | 2004 | 193 | 0.060 |
Why?
|
| Hand Deformities, Congenital | 1 | 2005 | 95 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2007 | 503 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2005 | 168 | 0.060 |
Why?
|
| Liver | 1 | 2014 | 3127 | 0.060 |
Why?
|
| Models, Biological | 2 | 2010 | 3221 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 1986 | 295 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2010 | 2457 | 0.060 |
Why?
|
| Stroke Volume | 2 | 2008 | 552 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 1423 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 1096 | 0.050 |
Why?
|
| Software | 2 | 2007 | 1392 | 0.050 |
Why?
|
| Neural Conduction | 1 | 2003 | 113 | 0.050 |
Why?
|
| San Francisco | 1 | 2003 | 24 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 170 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 4200 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2005 | 321 | 0.050 |
Why?
|
| London | 1 | 2002 | 14 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2003 | 118 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2018 | 12212 | 0.050 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2005 | 184 | 0.050 |
Why?
|
| Brain | 2 | 2014 | 4237 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 1177 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2010 | 1739 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2003 | 364 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2018 | 5832 | 0.050 |
Why?
|
| Bronchoconstriction | 1 | 2002 | 22 | 0.050 |
Why?
|
| Child Welfare | 1 | 2002 | 70 | 0.050 |
Why?
|
| Proteins | 1 | 2010 | 2058 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2004 | 585 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2001 | 16 | 0.050 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2001 | 19 | 0.050 |
Why?
|
| Chickenpox | 1 | 2001 | 34 | 0.050 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2001 | 15 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2001 | 44 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2007 | 1004 | 0.050 |
Why?
|
| Mediastinum | 1 | 2023 | 279 | 0.050 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2001 | 26 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2014 | 7300 | 0.050 |
Why?
|
| Parenting | 1 | 2005 | 353 | 0.050 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2001 | 39 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 2364 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2003 | 225 | 0.050 |
Why?
|
| Prostaglandins | 1 | 2001 | 84 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 641 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2001 | 128 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2000 | 52 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1741 | 0.050 |
Why?
|
| Pulmonary Veins | 1 | 2002 | 181 | 0.040 |
Why?
|
| Phenotype | 3 | 2018 | 6515 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2000 | 114 | 0.040 |
Why?
|
| Risk Factors | 5 | 2017 | 18028 | 0.040 |
Why?
|
| Pre-Excitation Syndromes | 1 | 2000 | 3 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 409 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 910 | 0.040 |
Why?
|
| Young Adult | 3 | 2018 | 22167 | 0.040 |
Why?
|
| Lactates | 1 | 2000 | 123 | 0.040 |
Why?
|
| Rhabdomyoma | 1 | 2000 | 23 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2019 | 37 | 0.040 |
Why?
|
| Apoptosis | 1 | 2014 | 7839 | 0.040 |
Why?
|
| Palliative Care | 4 | 2007 | 2171 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2001 | 138 | 0.040 |
Why?
|
| Myocarditis | 1 | 2001 | 182 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2004 | 690 | 0.040 |
Why?
|
| Pedigree | 2 | 2014 | 2045 | 0.040 |
Why?
|
| Desmoglein 2 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2004 | 1060 | 0.040 |
Why?
|
| Substance P | 1 | 1999 | 75 | 0.040 |
Why?
|
| Plakophilins | 1 | 2019 | 13 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2003 | 1581 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 729 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 1106 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2001 | 355 | 0.040 |
Why?
|
| Heart Septum | 2 | 2003 | 60 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 72 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2019 | 62 | 0.040 |
Why?
|
| Peroxidases | 1 | 2019 | 31 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 5940 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 197 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 5193 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1998 | 112 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2020 | 201 | 0.040 |
Why?
|
| Bronchi | 1 | 2000 | 330 | 0.040 |
Why?
|
| Pressure | 2 | 2011 | 190 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2019 | 2608 | 0.040 |
Why?
|
| Cytoprotection | 1 | 2018 | 66 | 0.040 |
Why?
|
| Trachea | 1 | 2000 | 290 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1606 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 657 | 0.040 |
Why?
|
| Tuberous Sclerosis | 1 | 2000 | 144 | 0.040 |
Why?
|
| Ligation | 1 | 1998 | 208 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 1999 | 124 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 700 | 0.040 |
Why?
|
| Body Patterning | 1 | 2019 | 207 | 0.040 |
Why?
|
| Patients | 1 | 2020 | 248 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 1233 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 10260 | 0.040 |
Why?
|
| Heart Neoplasms | 1 | 2000 | 216 | 0.040 |
Why?
|
| Calsequestrin | 1 | 2017 | 12 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2020 | 662 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2019 | 282 | 0.040 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 136 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2000 | 482 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 329 | 0.040 |
Why?
|
| Reference Values | 1 | 1999 | 1149 | 0.030 |
Why?
|
| Genotype | 2 | 2016 | 4276 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 297 | 0.030 |
Why?
|
| Embryonic Development | 1 | 2019 | 314 | 0.030 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Arginine | 1 | 1999 | 510 | 0.030 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2017 | 76 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 327 | 0.030 |
Why?
|
| Zebrafish | 1 | 2019 | 456 | 0.030 |
Why?
|
| Chest Pain | 1 | 2017 | 172 | 0.030 |
Why?
|
| Compliance | 1 | 2015 | 17 | 0.030 |
Why?
|
| Epoprostenol | 1 | 2016 | 86 | 0.030 |
Why?
|
| Equipment Design | 2 | 2011 | 1206 | 0.030 |
Why?
|
| Stents | 1 | 2002 | 1014 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2015 | 49 | 0.030 |
Why?
|
| Cineangiography | 1 | 1995 | 17 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 160 | 0.030 |
Why?
|
| Prognosis | 3 | 2018 | 22542 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 7238 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1999 | 893 | 0.030 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2017 | 240 | 0.030 |
Why?
|
| Infection Control | 1 | 2017 | 276 | 0.030 |
Why?
|
| Warfarin | 1 | 2016 | 152 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 1966 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 1078 | 0.030 |
Why?
|
| Lamin Type A | 1 | 2013 | 13 | 0.030 |
Why?
|
| Fibrillins | 1 | 2013 | 35 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2016 | 448 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3538 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2017 | 751 | 0.030 |
Why?
|
| Fibrillin-1 | 1 | 2013 | 59 | 0.030 |
Why?
|
| Patient Selection | 1 | 2001 | 2038 | 0.030 |
Why?
|
| Homozygote | 1 | 2016 | 771 | 0.030 |
Why?
|
| Tourniquets | 1 | 2013 | 15 | 0.030 |
Why?
|
| Thrombosis | 1 | 2019 | 754 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2021 | 886 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2014 | 249 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2017 | 447 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2019 | 6883 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 7925 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 972 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 1443 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 2600 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 2065 | 0.030 |
Why?
|
| Disease Progression | 2 | 2019 | 6904 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 235 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 4655 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 615 | 0.030 |
Why?
|
| Neuroglia | 1 | 2014 | 251 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 319 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1656 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2012 | 184 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 130 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 2363 | 0.020 |
Why?
|
| Eye Abnormalities | 1 | 2012 | 113 | 0.020 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 151 | 0.020 |
Why?
|
| Thorax | 1 | 1992 | 231 | 0.020 |
Why?
|
| Rheology | 1 | 2011 | 47 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2017 | 941 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2012 | 257 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2012 | 377 | 0.020 |
Why?
|
| Viscosity | 1 | 2011 | 45 | 0.020 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 313 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2011 | 150 | 0.020 |
Why?
|
| Ebstein Anomaly | 1 | 2010 | 26 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2251 | 0.020 |
Why?
|
| Genome, Human | 1 | 2019 | 1887 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 324 | 0.020 |
Why?
|
| Anesthesia | 2 | 2004 | 306 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2014 | 689 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 790 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2012 | 915 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1263 | 0.020 |
Why?
|
| Esophagus | 1 | 1992 | 564 | 0.020 |
Why?
|
| Oximetry | 1 | 2010 | 189 | 0.020 |
Why?
|
| Energy Transfer | 1 | 2008 | 37 | 0.020 |
Why?
|
| Tonga | 1 | 2008 | 1 | 0.020 |
Why?
|
| Stethoscopes | 1 | 2008 | 8 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2010 | 305 | 0.020 |
Why?
|
| Medical Audit | 1 | 2009 | 198 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 991 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 2824 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 1157 | 0.020 |
Why?
|
| Time | 1 | 2007 | 185 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 45 | 0.020 |
Why?
|
| Computers | 1 | 2007 | 141 | 0.020 |
Why?
|
| Malabsorption Syndromes | 1 | 1986 | 47 | 0.020 |
Why?
|
| Automation | 1 | 2007 | 153 | 0.020 |
Why?
|
| Sex Education | 1 | 2005 | 24 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 383 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 753 | 0.020 |
Why?
|
| Noble Gases | 1 | 2005 | 2 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 2246 | 0.020 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 206 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 1188 | 0.020 |
Why?
|
| Constriction | 1 | 2004 | 60 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2005 | 355 | 0.010 |
Why?
|
| Reproduction | 1 | 2005 | 277 | 0.010 |
Why?
|
| Karyotyping | 1 | 2005 | 1064 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2004 | 274 | 0.010 |
Why?
|
| Intensive Care, Neonatal | 1 | 2003 | 55 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 7832 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 2004 | 175 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2004 | 312 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2007 | 808 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 2048 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 633 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2007 | 1316 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2000 | 55 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 1407 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2006 | 9317 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 725 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 343 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 1364 | 0.010 |
Why?
|
| Hydrops Fetalis | 1 | 2000 | 74 | 0.010 |
Why?
|
| Tachycardia | 1 | 2000 | 84 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 1701 | 0.010 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2001 | 189 | 0.010 |
Why?
|
| Mesenteric Artery, Superior | 1 | 1999 | 77 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 486 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 1999 | 276 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2000 | 401 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 6237 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 1099 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 36023 | 0.010 |
Why?
|
| Methods | 1 | 1993 | 223 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 170 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 2534 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1995 | 680 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 7794 | 0.000 |
Why?
|
| Aged | 1 | 2005 | 73494 | 0.000 |
Why?
|
| Middle Aged | 1 | 2005 | 90447 | 0.000 |
Why?
|